I am Biotech

More than 15 million children in America live with a rare disease. Stories like that of Sammy Brazzo illuminate why the recent reauthorization of the program is critical to the rare pediatric community. This bipartisan program will continue to catalyze investment in rare pediatric disease research - accelerating the development of therapies for children who cannot afford to wait. This is Sammy's .

WATCH: Today, BIO President & CEO John F. Crowley gave his opening testimony before the House Energy & Commerce Subcommittee on Health, outlining how America can continue to lead the world in . In his remarks, John emphasized the following core priorities...

• Biotech as a national security imperative: With China rapidly scaling its biotech capabilities, maintaining U.S. leadership in biomedical innovation is essential to our economic strength, global competitiveness, and health security.

• Protecting America’s innovation ecosystem: Small and mid-sized biotech companies drive the majority of new medicines. They depend on strong IP protections, clear regulatory pathways, and a stable, market-based environment to sustain discovery.

• FDA predictability and efficiency: A science-driven, transparent, and well-resourced FDA is critical. Reducing time, cost, and complexity in development - and strengthening regulatory review - will accelerate patient access and keep the U.S. the global gold standard.

• Simplify the system and cut hidden supply chain costs: To address the real drivers of medicine affordability, policymakers must simplify the system and cut hidden supply chain costs that inflate what patients pay at the pharmacy counter.

• A roadmap for 21st century access: Removing financial and systemic barriers - capping out-of-pocket costs, reforming utilization management, and ensuring savings reach patients - will create a modern framework that puts patients first and improves long-term affordability.

As John made clear - there is not a moment to lose. America’s leadership - and patients’ lives - depend on our action today.